Ipratropium Steri-Neb Teva

Ipratropium bromide, the active ingredient in Ipratropium Steri-Neb Teva, is an anticholinergic (muscarinic antagonist) presented as a nebulizer solution for inhalation use. It treats chronic obstructive pulmonary disease (COPD) and asthma by relaxing airway smooth muscle and reducing mucus secretion. GNH USA supplies Ipratropium Steri-Neb Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is a bronchodilator that acts on the airways to relieve obstruction in chronic respiratory diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow, reduces dyspnea and lowers the frequency of exacerbations. - Asthma: provides additional bronchodilation when combined with other controller medications, helping to control symptoms and prevent bronchospasm. - Chronic bronchitis: decreases mucus secretion and eases cough by relaxing airway smooth muscle.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of reduced saliva production. - Cough or throat irritation: irritation from inhaled solution. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Nausea: occasional upset stomach. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Angioedema or severe allergic reaction: swelling of face, lips, or throat. - Urinary retention: difficulty emptying the bladder, especially in predisposed patients. - Increased intra‑ocular pressure: risk for patients with glaucoma.

When prescribing Ipratropium bromide, clinicians should consider several safety measures.

- Assess renal function: dose may need adjustment in severe renal impairment. - Avoid use in patients with narrow‑angle glaucoma: anticholinergic effect can raise intra‑ocular pressure. - Use cautiously in patients with urinary retention: may exacerbate symptoms. - Monitor for paradoxical bronchospasm: discontinue if severe breathing difficulty occurs. - Do not combine with other anticholinergic inhalers unless directed: risk of additive anticholinergic load. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other muscarinic antagonists (e.g., tiotropium): may cause excessive anticholinergic effects. - Combination with drugs that prolong QT interval: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: additive bronchodilation may increase heart rate. - Theophylline: possible increase in theophylline plasma levels. - Antihistamines: combined anticholinergic activity may enhance dry mouth and urinary retention.